RxDoctor Payments Data

Jonathan Sadler, DO

Psychiatry · Pearl, MSNPI 1932738119

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,835 and has fallen 62.9% since, to $680 in 2025.

$4,416in general payments, 2019–2025

Across 165 payments — averaging $26.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$933
  • Lundbeck LLC$513
  • Neurocrine Biosciences, Inc.$459
  • Otsuka America Pharmaceutical, Inc.$331
  • E.r. Squibb & Sons, L.L.C.$227
  • plus $949 from 10 others

What the payments were for

  • Food & beverage$4,33698%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,416 in reported general payments places this provider in the 85th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi

Medicare billing

Part B allowed, 2024
$4,470
Medicare patients
35
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$99,667
Abilify MaintenaAripiprazole21$61,288
Haloperidol Decanoate16$1,193
Quetiapine Fumarate61$1,136
Duloxetine Hcl18$1,039
Divalproex Sodium27$1,025
Aripiprazole36$1,002
Mirtazapine60$802
Ziprasidone Hcl14$736
Benztropine Mesylate44$517
Hydroxyzine Pamoate34$508
Quetiapine Fumarate ErQuetiapine Fumarate14$474
Clonazepam31$462
Venlafaxine Hcl ErVenlafaxine Hcl19$452
Trazodone Hcl54$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$459$99,66712 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$331$61,28821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Pearl

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →